Design, synthesis and cytotoxic evaluation of a selective serotonin reuptake inhibitor (SSRI) by virtual screening
European Journal of Pharmaceutical Sciences · 2023
DOI: 10.1016/j.ejps.2023.106403 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutical Sciences, 2023. Verfasst von Deissy N Jaramillo und 2 weiteren Autor:innen. Beteiligte Einrichtung: INQA, Applied Chemistry Research Group- Faculty of Chemistry, Universidad El Bosque, Bogotá, Colombia. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Paroxetine. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Universidad El Bosque, Kementerian Sains, Teknologi dan Inovasi.
Abstract (Originalsprache)
Depression is one of the most common mental illnesses, affecting almost 300 million people. According to the WHO, depression is one of the world's leading causes of disability and morbidity. People with this illness require both psychological and pharmaceutical treatment because severe depressive episodes often result in suicide. Selective serotonin reuptake inhibitors (SSRI) are widely used antidepressants that target the human serotonin transporter (hSERT). The crystallization of hSERT and the experimental data available allows cost and time-efficient computational tools like virtual screening (VS) to be utilized in the development of therapeutic agents. Here, we synthesized, characterized, and evaluated the biological activity of a novel SSRI analog of paroxetine, rationally designed by applying an artificial neural network-based QSAR model and a molecular docking analysis on hSERT. The analog N-substituted 18a showed higher affinity for the transporter (-10.2 kcal/mol), lower Ki value (1.19 nM) and a safer toxicological profile than paroxetine and was synthesized with a 71% yield. The in vitro cytotoxicity of the analog was evaluated using human glioblastoma (U87 MG), human neuroblastoma (SH SY5Y) and murine fibroblast (L929) cell lines. Also, the hemolytic ability of the compound was assessed on human erythrocytes. Results showed that analog 18a did not exhibit cytotoxic activity on the cell lines used and has no hemolytic activity at any of the concentrations tested, whereas with paroxetine, hemolysis was observed at 2.3, 1.29 y 0.67 mM. Based on these results, it is possible to suggest that analog 18a could be a promising new SSRI candidate for the treatment of this illness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INQA, Applied Chemistry Research Group- Faculty of Chemistry, Universidad El Bosque, Bogotá, Colombia.
- GIBAT, Basic and Traslational Research Group - Faculty of Medicine, Universidad El Bosque, Bogotá, Colombia.
- INQA, Applied Chemistry Research Group- Faculty of Chemistry, Universidad El Bosque, Bogotá, Colombia. Electronic address: joguevara@unbosque.edu.co.
Förderung
- Universidad El Bosque
- Kementerian Sains, Teknologi dan Inovasi
Zitieren
APA
Jaramillo, D. N., Millán, D., & Guevara-Pulido, J. (2023). Design, synthesis and cytotoxic evaluation of a selective serotonin reuptake inhibitor (SSRI) by virtual screening. European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2023.106403
Vancouver
Jaramillo DN, Millán D, Guevara-Pulido J. Design, synthesis and cytotoxic evaluation of a selective serotonin reuptake inhibitor (SSRI) by virtual screening. European Journal of Pharmaceutical Sciences. 2023. doi:10.1016/j.ejps.2023.106403
BibTeX
@article{Jaramillo2023,
author = {Jaramillo, Deissy N and Millán, Diana and Guevara-Pulido, James},
title = {Design, synthesis and cytotoxic evaluation of a selective serotonin reuptake inhibitor (SSRI) by virtual screening},
journal = {European Journal of Pharmaceutical Sciences},
year = {2023},
doi = {10.1016/j.ejps.2023.106403}
}
EUVIMED